Walk in interview in Quality Control and Quality Assurance at Ipca
Ipca is a fully integrated, rapidly growing Indian pharmaceutical company with a strong thrust on exports. Ipca's APIs and Formulations produced at worldclass manufacturing facilities are approved by leading drug regulatory authorities including the US-Food and Drug Administration (FDA), UK-Medicines and Healthcare products Regulatory Agency (MHRA), South Africa-Medicines Control Council (MCC), Brazil-Brazilian National Health Vigilance Agency (ANVISA) and Australia-Therapeutic Goods Administration (TGA). With operations in over 100 countries, exports account for over 52% of the company's income.

The flagship company of the Piramal Group, Piramal Enterprises Ltd. (PEL), has business interests in Pharma, Information Management, and Financial Services verticals of the group. Towards the late 80s, we shifted our focus from textile to pharmaceuticals. We chose to invest significantly in the domestic formulation development business, while other companies in the industry concentrated on international generics. Our efforts proved successful with a track record of approximately 23% revenue CAGR. In 2010, our strategy accomplished a sale of its domestic formulations business at an unprecedented value of ~9x sales and ~30x EBITDA.
